Cancer patients who responded to sotorasib can keep taking it in this safety follow-up study

NCT ID NCT07172919

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study is for people with advanced solid tumors who have a specific gene change (KRAS G12C) and are already doing well on sotorasib (with or without panitumumab) from a previous Amgen trial. It allows them to keep receiving the treatment while doctors monitor safety and side effects. About 14 adults who can take oral medication and have a life expectancy over 3 months may join.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Centre Leon Berard
RECRUITING

Lyon, 69008, France
Evangelische Lungenklinik
RECRUITING

Berlin, 13125, Germany
Florida Cancer Specialists - Fort Myers
RECRUITING

Fort Myers, Florida, 33901, United States
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITING

Roma, 00168, Italy
Henry Dunant Hospital Center
RECRUITING

Athens, 11526, Greece
National Hospital Organization Hokkaido Cancer Center
TERMINATED

Sapporo, Hokkaido, 003-0804, Japan
Scientia Clinical Research Ltd
TERMINATED

Randwick, New South Wales, 2031, Australia
Taichung Veterans General Hospital
RECRUITING

Taichung, 40705, Taiwan
Theagenion Cancer Hospital
RECRUITING

Thessaloniki, 54007, Greece
Universitaetsspital Basel
RECRUITING

Basel, 4031, Switzerland
University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.